Immutep (NASDAQ:IMMP) Share Price Passes Above 50-Day Moving Average – What’s Next?

Immutep Limited (NASDAQ:IMMP)’s stock price crossed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $1.99 and traded as high as $2.05. Immutep shares last traded at $1.95, with a volume of 104,357 shares.

Analyst Upgrades and Downgrades

Separately, Robert W. Baird lifted their target price on shares of Immutep from $6.00 to $7.00 and gave the company an “outperform” rating in a research report on Friday, November 15th.

Immutep Stock Up 4.6 %

The company has a current ratio of 18.25, a quick ratio of 18.25 and a debt-to-equity ratio of 0.01. The business has a fifty day simple moving average of $1.99 and a 200 day simple moving average of $2.16.

Institutional Investors Weigh In On Immutep

A number of large investors have recently modified their holdings of the business. Meridian Wealth Management LLC boosted its position in Immutep by 4.5% during the third quarter. Meridian Wealth Management LLC now owns 398,450 shares of the biotechnology company’s stock worth $881,000 after acquiring an additional 17,250 shares during the last quarter. XTX Topco Ltd purchased a new position in Immutep in the 2nd quarter worth approximately $26,000. Finally, XY Capital Ltd acquired a new position in shares of Immutep during the 2nd quarter worth approximately $105,000. Hedge funds and other institutional investors own 2.32% of the company’s stock.

Immutep Company Profile

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.